Search Results

Of the 13 programs that the companies will advance, four will come from Hengrui Pharma and four from Bristol Myers Squibb. The remaining five assets will be jointly discovered.

- Preclinical in vivo efficacy data in atopic dermatitis extend previous PoC in allergic asthma - Positive opinion from the European Patent Office strengthens patent protection of ATP-R13 - Progress significantly enhances the strategic attractiveness of ATP-R13 as a broadly applicable, disease-modifying therapy across multiple allergic indications